MARKET

BBIO

BBIO

BridgeBio Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

28.88
-0.45
-1.53%
Closed 19:13 06/01 EDT
OPEN
29.64
PREV CLOSE
29.33
HIGH
30.04
LOW
28.51
VOLUME
1.34M
TURNOVER
--
52 WEEK HIGH
48.36
52 WEEK LOW
14.23
MARKET CAP
3.51B
P/E (TTM)
-11.3242
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average BBIO stock price target is 44.78 with a high estimate of 51.00 and a low estimate of 37.00.

EPS

BBIO News

More
72 Biggest Movers From Friday
Gainers Adaptimmune Therapeutics plc (NASDAQ: ADAP) shares jumped 127.8% to close at $11.07 on Friday after the company announced updated data from its ADP-A2M4 Phase 1 trial at the American Society for Clinical Oncology Annual Meeting.
Benzinga · 1d ago
BridgeBio Pharma (BBIO) Investor Presentation - Slideshow
Seeking Alpha - Article · 3d ago
50 Stocks Moving In Friday's Mid-Day Session
Gainers
Benzinga · 3d ago
BridgeBio Pharmas QED Therapeutics Presents Data on Infigratinib in Cholangiocarcinoma and Urothelial Carcinoma at the American Society of Clinical Oncology 2020 Virtual Scientific Program
GlobeNewswire · 3d ago
BridgeBio Pharma Reports Its Affiliate QED To Present Data On Oral FGFR1-3 Inhibitor 'At ASCO
Benzinga · 3d ago
BTIG Initiates Coverage On BridgeBio Pharma with Buy Rating, Announces Price Target of $49
BTIG initiates coverage on BridgeBio Pharma (NASDAQ:BBIO) with a Buy rating and announces Price Target of $49.
Benzinga · 05/19 11:54
21 Stocks That Might Have Borrowed More Than Is Good For Them
Barrons.com · 05/19 11:45
21 Risky Stocks That Might Have Borrowed Too Much
marketwatch.com · 05/19 09:37

Industry

Pharmaceuticals
-1.07%
Pharmaceuticals & Medical Research
-0.77%

Hot Stocks

Symbol
Price
%Change

About BBIO

BridgeBio Pharma, Inc. is discovering and developing medicines that target well-characterized genetic diseases. The Company’s product platform divided into three key categories: Mendelian, Oncology and Gene therapy. The Company’s pipeline programs include product candidates ranging from early discovery to late-stage development. The Company’s products include BBP-265, BBP-831, BBP-631 and BBP-454.
More

Webull offers kinds of BridgeBio Pharma Inc stock information, including NASDAQ:BBIO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BBIO stock news, and many more online research tools to help you make informed decisions.